Case-control study of gadodiamide-related nephrogenic systemic fibrosis.

@article{Marckmann2007CasecontrolSO,
  title={Case-control study of gadodiamide-related nephrogenic systemic fibrosis.},
  author={Peter Marckmann and Lone Skov and Kristian Rossen and James Goya Heaf and Henrik S Thomsen},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2007},
  volume={22 11},
  pages={3174-8}
}
BACKGROUND Nephrogenic systemic fibrosis may be caused by gadolinium (Gd)-containing magnetic resonance imaging contrast agents. Most reported cases were associated with one particular agent, gadodiamide. Yet, unidentified cofactors might explain why only a minority of renal failure patients exposed to gadodiamide develop nephrogenic systemic fibrosis. METHODS We conducted a case-control study of 19 histologically verified cases and 19 sex- and age-matched controls. All subjects had chronic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 73 extracted citations

Magnetic resonance safety

Abdominal Radiology • 2016

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Gadolinium deposition in nephrogenic fibrosing dermopathy.

Journal of the American Academy of Dermatology • 2007
View 2 Excerpts

Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2006
View 2 Excerpts

Similar Papers

Loading similar papers…